EA201370025A1 - ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ - Google Patents

ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Info

Publication number
EA201370025A1
EA201370025A1 EA201370025A EA201370025A EA201370025A1 EA 201370025 A1 EA201370025 A1 EA 201370025A1 EA 201370025 A EA201370025 A EA 201370025A EA 201370025 A EA201370025 A EA 201370025A EA 201370025 A1 EA201370025 A1 EA 201370025A1
Authority
EA
Eurasian Patent Office
Prior art keywords
sapp
mimetics
reproduction
optionally substituted
storage
Prior art date
Application number
EA201370025A
Other languages
English (en)
Other versions
EA028215B1 (ru
Inventor
Валентин Георгиевич НЕНАЙДЕНКО
Сергей Евгеньевич ТКАЧЕНКО
Сергей Олегович БАЧУРИН
Владимир Евгеньевич КАБАКОВ
Константин Владимирович АНОХИН
Original Assignee
Общество С Ограниченной Ответственностью "Биофарм-Меморейн"
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Биофарм-Меморейн" filed Critical Общество С Ограниченной Ответственностью "Биофарм-Меморейн"
Publication of EA201370025A1 publication Critical patent/EA201370025A1/ru
Publication of EA028215B1 publication Critical patent/EA028215B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Изобретение относится к новому классу непептидных гетероциклических низкомолекулярных пептидомиметиков секреторного предшественника амилоидного пептида sAPP (sAPP-миметиков), обладающих способностью эффективно воздействовать на процессы формирования, хранения и воспроизведения памяти, утраченной в норме и патологии. Соединения также могут найти применение для исследований (in vitro и in vivo)биохимических сигнальных, нейротрофических и нейропротекторных процессов, связанных с секреторным белком sAPP, и механизмов формирования, хранения и воспроизведения памяти. Конкретно изобретение относится к (азагетероциклил)алкильным производным амидам 2-(гет)арилглицинов общей формулы Iв которой n и m могут принимать значения 0, 1, 2 и 3; знак (#) здесь и далее обозначает возможность наличия хирального центра; R представляет необязательно замещенный C-Cарил или 5-7-членный гетарил, содержащий 1-3 гетероатома, выбранных из азота, кислорода и серы, возможно конденсированный с бензольным кольцом; А1 и А2 независимо представляют необязательно замещенный 3-7-членный насыщенный, частично насыщеный или ароматический азагетероцикл, содержащий от 1 до 3 атомов азота в цикле и возможно конденсированный с бензольным кольцом; или их фармацевтически приемлемые соли или сложные алкиловые эфиры в виде отдельных оптических изомеров или их смесей.
EA201370025A 2010-08-31 2011-08-30 ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ EA028215B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010135900/04A RU2465273C2 (ru) 2010-08-31 2010-08-31 ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
PCT/RU2011/000662 WO2012030258A1 (ru) 2010-08-31 2011-08-30 Гетероциклические низкомолекулярные sapp-миметики, фармацевтическая композиция, способы получения и применения

Publications (2)

Publication Number Publication Date
EA201370025A1 true EA201370025A1 (ru) 2013-08-30
EA028215B1 EA028215B1 (ru) 2017-10-31

Family

ID=45773119

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201370025A EA028215B1 (ru) 2010-08-31 2011-08-30 ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ

Country Status (5)

Country Link
US (1) US20220135547A1 (ru)
EP (1) EP2626352A4 (ru)
EA (1) EA028215B1 (ru)
RU (1) RU2465273C2 (ru)
WO (1) WO2012030258A1 (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10634677B2 (en) 2013-10-14 2020-04-28 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW449590B (en) * 1995-04-14 2001-08-11 Boehringer Ingelheim Kg New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
US6552013B1 (en) * 1998-06-22 2003-04-22 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
US6630451B1 (en) 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
US6858577B1 (en) 1999-06-29 2005-02-22 Ortho-Mcneil Pharmaceutical, Inc. Indole peptidomimetics as thrombin receptor antagonists
BR0315158A (pt) * 2002-10-09 2005-08-16 Pfizer Prod Inc Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
CA2544350A1 (en) * 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
CN1934091B (zh) * 2004-03-23 2012-02-08 辉瑞产品公司 治疗神经变性障碍的咪唑化合物
US20100048656A1 (en) 2007-02-01 2010-02-25 Nadia Mamoona Ahmad Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
EP2108018A2 (en) 2007-02-01 2009-10-14 Glaxo Group Limited 8-oxa-1,4-diazaspiro [4,5] dec-3-en-1-yl and 1,4,8-triazaspiro [4,5] dec-3-en-1-yl acetamides as glyti transporter inhibitors in treatment of neurological and neuropsychiatric disorders
MX2010008021A (es) * 2008-01-29 2010-08-04 Hoffmann La Roche Nuevos derivados de n-(2-amino-fenil)-amida.

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10634677B2 (en) 2013-10-14 2020-04-28 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
US11733243B2 (en) 2013-10-14 2023-08-22 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD

Also Published As

Publication number Publication date
WO2012030258A1 (ru) 2012-03-08
EP2626352A4 (en) 2014-06-04
RU2465273C2 (ru) 2012-10-27
EP2626352A1 (en) 2013-08-14
US20220135547A1 (en) 2022-05-05
EA028215B1 (ru) 2017-10-31
RU2010135900A (ru) 2012-04-10

Similar Documents

Publication Publication Date Title
EA201071035A1 (ru) Фармацевтические композиции модифицированного высвобождения, содержащие микофенолат, и способ их получения
DOP2012000151A (es) Nuevos compuestos triciclicos
AR075139A1 (es) Compuestos biciclicos para la reduccion de la produccion de beta-amiloide
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
WO2009006404A3 (en) Heterocyclic compounds useful as raf kinase inhibitors
GT201200346A (es) Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica
NO20080391L (no) Pyrazolbaserte LXR modulatorer
CO6290658A2 (es) Derivados de azetidina y ciclobutano como inhibidores de jack
AR070221A1 (es) Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
UA111933C2 (uk) Піролопіридини як інгібітори кінази
PE20080988A1 (es) Compuestos triciclicos fusionados de sulfonamida como inhibidores de gama-secretasa
CR20120524A (es) Combinaciones que contienen 2,3-dihidroimidazo [1,2-c] quinazolina sustituida
Muth et al. Development of radamide analogs as Grp94 inhibitors
ECSP077997A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
EA201070483A1 (ru) Новые офтальмологические композиции
PE20081700A1 (es) Derivados de acido de piranona sustituidos como agentes para tratar el sindrome metabolico
AR097721A1 (es) Derivados de etinilo
AR084944A1 (es) COMPUESTOS PARA REDUCIR LA PRODUCCION DE AMILOIDE b
Bisi et al. Polycyclic maleimide-based derivatives as first dual modulators of neuronal calcium channels and GSK-3β for Alzheimer's disease treatment
EA201291327A1 (ru) Замещенные 6-метилникотинамиды как позитивные аллостерические модуляторы mglur5
EA201370025A1 (ru) ГЕТЕРОЦИКЛИЧЕСКИЕ НИЗКОМОЛЕКУЛЯРНЫЕ sAPP-МИМЕТИКИ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
Ahmadian et al. Podocytopathy: The role of actin cytoskeleton
CY1118595T1 (el) Αρυλοαιθινυλο πυριμιδινες
ECSP088988A (es) Derivados de ácido fenilacético

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU